Get the Stockscreener App
1.13
8.65%
0.09
After Hours:
1.10
-0.03
-2.65%
Chemomab Therapeutics Ltd Adr stock is traded at $1.13, with a volume of 196.47K.
It is up +8.65% in the last 24 hours and down -32.74% over the past month.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
See More
Previous Close:
$1.04
Open:
$1.04
24h Volume:
196.47K
Relative Volume:
0.56
Market Cap:
$19.61M
Revenue:
-
Net Income/Loss:
$-33.08M
P/E Ratio:
-0.3844
EPS:
-2.94
Net Cash Flow:
$-25.68M
1W Performance:
-2.59%
1M Performance:
-32.74%
6M Performance:
-25.17%
1Y Performance:
+48.29%
1-Day Range:
$1.0339
$1.2492
1-Week Range:
$0.92
$1.35
52-Week Range:
$0.579
$2.55
Chemomab Therapeutics Ltd Adr Stock (CMMB) Company Profile
Name
Chemomab Therapeutics Ltd Adr
Sector
Industry
Phone
972-77-331-0156
Address
KIRYAT ATIDIM, BUILDING 7, TEL AVIV
Compare CMMB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMMB
Chemomab Therapeutics Ltd Adr
|
1.13 | 19.61M | 0 | -33.08M | -25.68M | -2.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Chemomab Therapeutics Ltd Adr Stock (CMMB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-13-24 | Initiated | Maxim Group | Buy |
| May-06-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Dec-19-23 | Resumed | ROTH MKM | Buy |
Chemomab Therapeutics Ltd Adr Stock (CMMB) Latest News
The Aurora Cannabis Inc (NASDAQ: ACB) Stock Price: Is It Overvalued? - Stocks Register
How Stable And Growing Is Globavend Holdings Ltd (NASDAQ: GVH)? - Stocks Register
Before Buying AYRO Inc (NASDAQ: AYRO) Stock, Read This First - Stocks Register
Is Advance Auto Parts Inc (NYSE: AAP) A Good Investment For New Investors Now? - stocksregister.com
Nu Holdings Ltd (NYSE: NU) Has Great Upside Potential - stocksregister.com
ZEEKR Intelligent Technology Holding Ltd. ADR (NYSE: ZK): Getting A Free Pass? - stocksregister.com
AT&T, Inc (NYSE: T) Jumps 1.59%: What Could Be On The Way Going Forward? - Stocks Register
Adma Biologics Inc (NASDAQ: ADMA): Blank Check For Growth? - Stocks Register
A Bullish 2025 Outlook For Blink Charging Co (NASDAQ: BLNK) Shares - Stocks Register
In 2025, Linkers Industries Ltd (NASDAQ: LNKS) Shares Will Likely Be Bullish - Stocks Register
Carrier Global Corp (NYSE: CARR): On Track To A Higher Share Price - Stocks Register
Before Buying Avantor Inc (NYSE: AVTR) Stock, Read This First - stocksregister.com
Ally Financial Inc (NYSE: ALLY): An Enticing Stock To Watch - stocksregister.com
Does DLocal Limited (NASDAQ: DLO) Still Need To Convince Analysts? - stocksregister.com
What Is Going On With Ondas Holdings Inc (NASDAQ: ONDS)? - stocksregister.com
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA)’s Stock Boosts 3.25%, But It May Be A Worthy Investment - stocksregister.com
Chemomab Therapeutics (CMMB) Stock Price, News & Analysis - MarketBeat
How analysts predict Chemomab Therapeutics Ltd ADR (CMMB) will perform this quarter? - US Post News
LogicMark Inc (LGMK) Recovers 0.71% From Low: Are We There Yet? - Stocks Register
Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis - GlobeNewswire Inc.
Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update - Investing.com
Chemomab reports progress in PSC treatment trial - Investing.com
Roth MKM Initiates Coverage of Chemomab Therapeutics LtdADR (CMMB) with Buy Recommendation - MSN
The Chemomab Therapeutics Ltd ADR (CMMB) had a good session last reading, didn’t it? - US Post News
Ratios Uncovered: Breaking Down Chemomab Therapeutics Ltd ADR (CMMB)’s Trailing Twelve Months Metrics - The Dwinnex
symbol__ Stock Quote Price and Forecast - CNN
Intercept (ICPT) Gains 12.4% in the Past Six Months: Here's Why - Zacks Investment Research
Chemomab And AGC Biologics Partner To Manufacture CM-101 For Phase II/III - Contract Pharma
What You Need To Know About Chemomab Therapeutics Ltd.'s (NASDAQ:CMMB) Investor Composition - Yahoo Finance
CMMB News Today | Why did Chemomab Therapeutics stock go down today? - MarketBeat
The Daily Biotech Pulse: Novartis Gets Adcom Backing, Sio Gene Data, 2 IPOs, BioNTech Clinches China Vaccine Supply Deal - Yahoo Finance
Chemomab Therapeutics Ltd Adr Stock (CMMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):